Influence of the metabolic syndrome on leptin and leptin receptor in breast cancer

✍ Scribed by Paul A. Carroll; Laura Healy; Joanne Lysaght; Terry Boyle; John V. Reynolds; M. John Kennedy; Graham Pidgeon; Elizabeth M. Connolly

• Publisher: John Wiley and Sons
• Year: 2011
• Tongue: English
• Weight: 165 KB
• Volume: 50
• Category: Article
• ISSN: 0899-1987
• DOI: 10.1002/mc.20764

✦ Synopsis

Abstract

Obesity and its associated metabolic syndrome (MetS) are recognized risk factors for breast cancer. The molecular basis for this association remains largely unknown. Adipokines, in particular leptin and adiponectin, are thought to form part of the mechanism linking obesity with cancer through their altered expression/production either systemically (endocrine pathway) or locally (paracrine/autocrine pathway). Using quantitative PCR, mRNA expression of adiponectin (AdipoQ) and leptin (Ob) in mammary adipose tissue (MAT), intratumoral leptin and associated ligand receptors (ObR, AdipoR1, and AdipoR2) was examined in 77 patients with complete anthropomorphic and serological data. Expression of Ob in MAT, and ObR in matched tumor tissue was significantly higher in patients with MetS compared to obese only or normal weight cancer patients (P < 0.005). There was no difference in intratumoral leptin adiponectin or its ligand receptors in the same groups. Individual features of MetS correlated with Ob and ObR expression, but not obesity markers (BMI, waist circumference). mRNA expression of leptin (Ob) and ObR, in adipose tissue and matched tumor samples, respectively, appear to be associated with obesity status in breast cancer. Increasing insulin resistance is a predominant feature of this higher Ob/ObR expression observed. These novel data indicate that the MetS may be an amenable risk factor for breast cancer. © 2011 Wiley‐Liss, Inc.